| [1] |
ZHAO Xuan, GUO Jing, CHEN Ning, MEI Long, ZHENG Tingting, ZHANG Lifang, ZHANG Wei.
Discuss the safety management of medical toxic drugs in medical institutions
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 705-708.
|
| [2] |
ZHENG Yujing, ZHAO Zinan, JIN Pengfei, ZHAO Fei, HU Xin, ZHANG Yatong.
Active monitoring of adverse reactions of capecitabine-induced hand-foot syndrome based on the hospital information system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 441-443.
|
| [3] |
HU Biyuan, WANG Jing, ZHENG Weiqi, HU Hongping, CHEN Yongwu.
Suicidal tendency and paresthesia induced by voriconazole: a case report
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 469-472.
|
| [4] |
ZHONG Yingying, WANG Zhao, ZUO Tiantian, LI Yaolei, LI Hailiang, MA Shuangcheng.
Research progress on detection and risk assessment of exogenous heavy metals and related elements in Codonopsis Radix
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1309-1315.
|
| [5] |
YANG Miao, YANG Li, ZHAO Zhigang.
Current applications and rationality of ribavirin in pediatrics in seven cities in China
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 408-412.
|
| [6] |
LI Lan, KONG Fanyao, ZHU Ying, SHEN Lu.
Developments and Suggestions on Cosmetics Adverse Reaction Monitoring in China
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 850-854.
|
| [7] |
WANG Dan, REN Jingtian, WU Guizhi, XIONG Weiyi, TANG Ren, PANG Yu, FAN Rong, YANG Le.
Significance of Good Pharmacovigilance Practice in the Construction of China Pharmacovigilance System
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 501-503.
|
| [8] |
GENG Hongjiao, WANG Lianxin, XIE Yanming.
Pharmacovigilance of Chinese Medicine in Medical Institutions
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 552-555.
|
| [9] |
SA Rina, ZHANG Bing, LIN Zhijian, WANG Xiaofang, ZHANG Xiaomeng.
Pharmacovigilance of Traditional Chinese Medicine in Pharmaceutical Care in Medical Institutions
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 422-426.
|
| [10] |
FENG Yanan, LIU Xinxin, LI Yonghui, WANG Fang, GUO Ruifeng.
Challenges to Pharmacovigilance by Medical Institutions under the New Drug Administration Law
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(9): 572-573.
|
| [11] |
HUANG Yuan, WANG Chenggang, WU Shifu, WANG Ling, TIAN Yuejie, WU Chen, WANG Xiaojun.
Drug Abuse Monitoring Models in Medical Institutions in China
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(9): 607-612.
|
| [12] |
WANG Dan, REN Jingtian, DONG Duo, PENG Lili, LIU Wei.
Trend Analysis of Ten-year Annual Reports on Adverse Drug Reaction Monitoring
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(5): 276-283.
|
| [13] |
YUAN Lin, GAOYan, LU Changfei.
Preliminary Thinking on the Establishment of Pharmacovigilance System in China
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 749-752.
|
| [14] |
WAN Kaihua, WEI Yu, XU Yuming, ZHOU Juan.
Current Status of Drug Abuse Epidemic and Intervention Research in China
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(6): 338-341.
|
| [15] |
LI Jianguo, QIN Xiujun, HU Bo, GAO Jie, LI Mei, LIU Huan, AN Quan, JIN Hongtao.
Research Status and Prospect of Radiopharmaceuticals
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(1): 27-31.
|
